Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer

Fineline Cube May 12, 2026
Company Deals

China Medical System Secures Exclusive China Rights to Pharmacosmos’ MonoFer and CosmoFer IV Iron Therapies

Fineline Cube May 12, 2026
Company Deals

Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization

Fineline Cube May 12, 2026
Company Deals

Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market

Fineline Cube May 12, 2026
Company Deals

Hybio Pharmaceutical Licenses GLP-1 Copycats to MCG Pharma for Exclusive Turkish Commercialization

Fineline Cube May 12, 2026
Policy / Regulatory

NMPA Releases 105th Batch of Generic Drug Reference Standards, Adding 37 New Specifications

Fineline Cube May 12, 2026
Company Drug

CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer

Fineline Cube May 12, 2026
Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Fineline Cube May 12, 2026
Company Medical Device

Peijia Medical’s YonFlow Stent Approved by China’s NMPA

Fineline Cube Apr 10, 2025

Peijia Medical Ltd (HKG: 9996) announced that it has received market approval from China’s National...

Company Medical Device

Gaush Meditech’s Corneal Confocal Microscope Approved in Jiangsu

Fineline Cube Apr 10, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced that it has received market approval from the...

Company Drug

Simcere Pharmaceutical Gains NMPA Approval for FGFR2b-Targeted ADC SIM0686

Fineline Cube Apr 10, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the National...

Company Deals

Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply

Fineline Cube Apr 10, 2025

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed...

Policy / Regulatory

U.S. Tariffs on Pharmaceuticals and Their Impact on China’s Medical Industry

Fineline Cube Apr 9, 2025

The U.S. administration’s decision to impose tariffs on pharmaceutical imports, effective April 9, has sent...

Company Drug

Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma

Fineline Cube Apr 9, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in...

Company Drug

AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis

Fineline Cube Apr 9, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval in the...

Company Drug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer

Fineline Cube Apr 9, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced this week that the US Food and Drug Administration...

Company Drug

Yifan Pharma Secures NMPA Approval for Generic Sedapain

Fineline Cube Apr 9, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that it has received marketing approval...

Company Drug

Yunnan Baiyao’s INR102 Gains NMPA Clinical Trial Clearance for Prostate Cancer

Fineline Cube Apr 9, 2025

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...

Company Deals

Shanghai Kehua Bioengineering Launches Xi’an Medical Complex Project

Fineline Cube Apr 9, 2025

Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a leading Chinese biotechnology company, has announced plans...

Company Deals

HuidaGene’s hfCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy

Fineline Cube Apr 9, 2025

Shanghai-based genome medicines specialist HuidaGene Therapeutics has sublicensed its hfCas12Max platform to Vita Therapeutics, Inc.,...

Policy / Regulatory

NMPA Optimizes Drug Manufacturing License Process with Digital QR Codes

Fineline Cube Apr 9, 2025

The National Medical Products Administration (NMPA) has announced new measures to optimize the drug manufacturing...

Company Drug

Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU

Fineline Cube Apr 9, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing...

Company Deals

Aidea Pharma Terminates COVID-19 Drug Collaboration with PharmaBlock

Fineline Cube Apr 9, 2025

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the termination of its development collaboration...

Company Drug

Daiichi Sankyo and AstraZeneca’s Datroway Approved in EU for Breast Cancer

Fineline Cube Apr 9, 2025

Japan-based Daiichi Sankyo (TYO: 4568) and UK major AstraZeneca (NASDAQ: AZN) announced that their co-developed...

Company Deals

IDT and Shanghai Bioscience Forge Partnership to Drive Local Innovation in China

Fineline Cube Apr 9, 2025

Integrated DNA Technologies (IDT), a leading life sciences and diagnostics company under the Danaher Corporation...

Company

Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales

Fineline Cube Apr 9, 2025

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD...

Company Drug

Winsunny Pharma’s FY101 Gains NMPA Clinical Approval for Hyperlipidemia

Fineline Cube Apr 9, 2025

China-based Beijing Winsunny Pharmaceutical Co., Ltd (SHA: 601089) announced that it has received clinical approval...

Company Medical Device

HighLife SAS’s TMVR System Receives FDA Breakthrough Device Designation

Fineline Cube Apr 9, 2025

Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996),...

Posts pagination

1 … 178 179 180 … 664

Recent updates

  • Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer
  • NMPA Releases 105th Batch of Generic Drug Reference Standards, Adding 37 New Specifications
  • China Medical System Secures Exclusive China Rights to Pharmacosmos’ MonoFer and CosmoFer IV Iron Therapies
  • Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization
  • Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer

Policy / Regulatory

NMPA Releases 105th Batch of Generic Drug Reference Standards, Adding 37 New Specifications

Company Deals

China Medical System Secures Exclusive China Rights to Pharmacosmos’ MonoFer and CosmoFer IV Iron Therapies

Company Deals

Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.